AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04563338
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
Trial: NCT03826693
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
Trial: NCT03826693
Drug: Nitrogen
RxNorm normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
Trial: NCT05373264
Drug: Hydrochlorothiazide 25 mg
RxNorm normalized name: hydrochlorothiazide 25 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An oral capsule containing 25mg of hydrochlorothiazide
Trial: NCT04656002
Drug: Vactosertib
RxNorm normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
Trial: NCT05173493
Drug: Amoxicillin,Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Furazolidone-containing quadruple group
Trial: NCT05173493
Drug: Amoxicillin,Levofloxacin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Levofloxacin-containing quadruple group
Trial: NCT06630416
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04905316
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
Trial: NCT04905316
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
Trial: NCT05648526
Drug: ACTH4-10Pro8-Gly9-Pro10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
Trial: NCT05648526
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: negative-positive control (ketamine 40 mg/kg BW subcutaneously)
Trial: NCT05377619
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
Trial: NCT05377619
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
Trial: NCT06109207
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
Trial: NCT06109207
Drug: Dalpiciclib 100mg
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Trial: NCT06109207
Drug: Dalpiciclib 150mg
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Trial: NCT06363539
Drug: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION
RxNorm normalized name: Clobetasol Propionate .05 mg in 100 mL TOPICAL LOTION
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: steroid used for umblical granuloma
Trial: NCT06363539
Drug: Silver Nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: silver nitrate used for treatment
Trial: NCT04780464
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
Trial: NCT04745767
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T2 formulation.
Trial: NCT04745767
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1 formulation.
Trial: NCT04745767
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3 formulation.
Trial: NCT04745767
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4 formulation.
Trial: NCT04745767
Drug: TAK-994
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T5 formulation.
Trial: NCT06358638
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
Trial: NCT06358638
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
Trial: NCT06358638
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
Trial: NCT05593627
Drug: Lithium Carbonate 250 MG Oral Tablet
RxNorm normalized name: lithium carbonate 250 MG Oral Tablet
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
Trial: NCT05584228
Drug: Azathioprine + infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
Trial: NCT03999840
Drug: cemdisiran
RxNorm normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
Trial: NCT06270433
Drug: Toludesvenlafaxine hydrochloride sustained-release tablets
RxNorm normalized name: bupropion
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
Trial: NCT06270433
Drug: Desvenlafaxine succinate sustained-release tablets
RxNorm normalized name: desvenlafaxine succinate Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg orally once daily dosing for 8 weeks
Trial: NCT04860141
Drug: Gabapentin 600mg
RxNorm normalized name: GABAPENTIN 600MG TAB
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will take gabapentin 600mg 2 hours prior to the procedure
Trial: NCT04759131
Drug: efanesoctocog alfa (BIVV001)
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: IV
Trial: NCT02376751
Drug: sebelipase alfa
RxNorm normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04841551
Drug: Kybella Flanks
RxNorm normalized name: Kybella
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 subjects will be treated with Kybella in the flanks
Trial: NCT05576818
Drug: Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
Trial: NCT06447402
Drug: Amphotericin B deoxycholate
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
Trial: NCT05171439
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Trial: NCT04065152
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec
Trial: NCT04660370
Drug: CKD-348
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05150717
Drug: [14C]-Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
Trial: NCT05296564
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
Trial: NCT06154486
Drug: semaglutide use
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patient using semaglutide for at least 7 days
Trial: NCT05003596
Drug: Methylprednisolone Tablet
RxNorm normalized name: Methylprednisolone Tablets
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take a quantity 21 4mg tablets over a 6 week taper.
Trial: NCT05037617
Drug: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.
Trial: NCT06141265
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Trial: NCT04534322
Drug: Melphalan Flufenamide
RxNorm normalized name: melphalan flufenamide
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
Trial: NCT04534322
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
Trial: NCT06209359
Drug: Ammonium Chloride
RxNorm normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
Trial: NCT05933720
Drug: Polypeptides
RxNorm normalized name: gelatin polypeptides
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
Trial: NCT05823701
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
Trial: NCT05823701
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg d1- d5 subcutaneous injection per cycle
Trial: NCT05823701
Drug: Liposomal mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m2 d5 intravenous infusion per cycle
Trial: NCT05957848
Drug: Guanfacine Extended Release Oral Tablet
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Target dose 4 mg daily
Trial: NCT05411367
Drug: SI-614
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye
Trial: NCT06444802
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
Trial: NCT04808622
Drug: Trans-Sodium Crocetinate
RxNorm normalized name: Codium tomentosum extract
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSC given as a one-time IV bolus injection
Trial: NCT03926819
Drug: HBI-002
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid carbon monoxide drug product.
Trial: NCT06026878
Drug: gemcitabine,nimotuzumab, toripalimab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: same as before
Trial: NCT06026878
Drug: gemcitabine, cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: same as before
Trial: NCT05149365
Drug: Sitagliptin + Standard Prophylaxis
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
Trial: NCT06389318
Drug: buccal midazolam +oral placebo syrup
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
Trial: NCT06389318
Drug: oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
Trial: NCT06582628
Drug: Enzalutamide capsule
RxNorm normalized name: Enzalutamide Capsules
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide capsules 160 mg orally daily
Trial: NCT06582628
Drug: Enzalutamide capsule and Talazoparib capsule
RxNorm normalized name: enzalutamide Oral Capsule
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
Trial: NCT00002290
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002290
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04793139
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
Trial: NCT05889390
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly paclitaxel for 12 weeks
Trial: NCT05889390
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: added to weekly paclitaxel if patient has triple-negative breast cancer
Trial: NCT05995782
Drug: FB418
RxNorm normalized name: Fostamatinib
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral dose
Trial: NCT05805891
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bortezomib 2mg/week subcutaneous injection
Trial: NCT04467515
Drug: CAM-H2
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
DrugBank: Phendimetrazine (DB01579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
Trial: NCT00000712
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000712
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04531215
Drug: ultrasound guided Retrolaminar Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
Trial: NCT05953350
Drug: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
RxNorm normalized name: COMBINATIONS OF ANTIBACTERIALS
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.